文献速递结核与非结核分枝杆菌

全球、区域和国家层面实现世界卫生组织终结结核病策略2020年阶段性目标的年龄别进展:2021年全球疾病负担研究的系统分析

Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
PubMed 文献 · Lancet Infect Dis · 2024-03-19

基于2021年全球疾病负担研究框架,估算1990至2021年204个国家和地区的年龄别结核病发病率与死亡率,评估2015至2020年WHO终结结核病策略阶段性目标进展。2015至2020年全年龄结核病发病率下降6.26%,仅15个国家达到发病率下降20%的目标;全球结核病死亡下降11.9%,仅17个国家达到死亡下降35%的目标,70岁及以上人群死亡下降3.29%为各年龄组最慢。

要点

  • 2015至2020年全球全年龄结核病发病率下降6.26%,仅15个国家达到下降20%的阶段性目标。
  • 2015至2020年全球结核病死亡下降11.9%,仅17个国家达到下降35%的阶段性目标。
  • 年龄别进展不均,70岁及以上人群结核病死亡仅下降3.29%,为各年龄组中最慢。

核心结论

  • 尽管过去十年全球结核病负担下降加速,但世界未能在2020年实现WHO终结结核病策略的首个阶段性目标。
  • 下降速度在年龄间不均衡,50岁及以上老年人进展最慢。
  • 各国在调整国家结核病规划以实现2035年目标时,可考虑借鉴已实现2020年阶段性目标国家的策略,并考虑针对老年年龄组采取靶向干预以改善结局。

研究设计与样本

  • 研究采用2021年全球疾病负担、伤害与危险因素研究(GBD 2021)分析框架,计算204个国家和地区1990至2021年年龄别结核病死亡率与发病率估计。
  • 无HIV合并感染的结核病死亡估计使用22603站点年生命登记数据、1718站点年口头尸检数据、825站点年抽样生命登记数据、680站点年死亡监测数据和9站点年微创组织样本诊断数据,输入死因集合建模平台。
  • 年龄别HIV与结核病死亡采用人群归因分值方法确定。
  • 采用DisMod-MR 2.1分析现有基于人群的数据来源(包括患病率调查、年度病例报告、结核菌素调查和结核病死亡),产生内部一致的年龄别结核病发病率、患病率和死亡率估计。
  • 二次分析通过比较基于2015至2019年生命登记数据趋势建模的期望结核病死亡与2020年和2021年观察到的结核病死亡,评估COVID-19大流行对无HIV合并感染结核病死亡的潜在影响。

主要发现

  • 2015至2020年全球全年龄结核病发病率下降6.26%(5.27至7.25);204个国家中15个实现全年龄结核病发病率下降20%,其中8个位于撒哈拉以南非洲西部。
  • 2015至2020年年龄别结核病发病率下降:5岁以下儿童下降16.5%(14.8至18.4),5至14岁下降16.2%(14.2至17.9),15至49岁下降6.29%(5.05至7.70),50至69岁下降5.72%(4.02至7.39),70岁及以上下降8.48%(6.74至10.4)。
  • 2015至2020年全球结核病死亡下降11.9%(5.77至17.0);17个国家实现结核病死亡下降35%,多数位于东欧(6个国家)和中欧(4个国家)。
  • 年龄别结核病死亡下降:5岁以下儿童下降35.3%(26.7至41.7),5至14岁下降29.5%(25.5至34.1),15至49岁下降15.2%(10.0至20.2),50至69岁下降7.97%(0.472至14.1),70岁及以上下降3.29%(-5.56至9.07)。

关键数值与推荐

  • WHO终结结核病策略2020年阶段性目标为死亡率下降35%、发病率下降20%。
  • 2015至2020年为WHO终结结核病策略评价期。
  • COVID-19影响分析纳入2020年41个国家和2021年20个国家;2020年全年龄期望死亡50900例(95%CI 49700至52400),观察死亡45500例,即减少5340例(4070至6920);2021年期望死亡39600例(95%CI 38300至41100),观察死亡39000例,即减少657例(-713至2180)。

临床怎么用

  • 作者认为,各国在调整国家结核病规划以实现2035年目标时,可考虑借鉴已实现2020年阶段性目标国家的策略。
  • 作者认为,各国可考虑采取针对老年年龄组的靶向干预以改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Global evaluations of the progress towards the WHO End TB Strategy 2020 interim milestones on mortality (35% reduction) and incidence (20% reduction) have not been age specific. We aimed to assess global, regional, and national-level burdens of and trends in tuberculosis and its risk factors across five separate age groups, from 1990 to 2021, and to report on age-specific progress between 2015 and 2020. METHODS: We used the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021) analytical framework to compute age-specific tuberculosis mortality and incidence estimates for 204 countries and territories (1990-2021 inclusive). We quantified tuberculosis mortality among individuals without HIV co-infection using 22 603 site-years of vital registration data, 1718 site-years of verbal autopsy data, 825 site-years of sample-based vital registration data, 680 site-years of mortality surveillance data, and 9 site-years of minimally invasive tissue sample (MITS) diagnoses data as inputs into the Cause of Death Ensemble modelling platform. Age-specific HIV and tuberculosis deaths were established with a population attributable fraction approach. We analysed all available population-based data sources, including prevalence surveys, annual case notifications, tuberculin surveys, and tuberculosis mortality, in DisMod-MR 2.1 to produce internally consistent age-specific estimates of tuberculosis incidence, prevalence, and mortality. We also estimated age-specific tuberculosis mortality without HIV co-infection that is attributable to the independent and combined effects of three risk factors (smoking, alcohol use, and diabetes). As a secondary analysis, we examined the potential impact of the COVID-19 pandemic on tuberculosis mortality without HIV co-infection by comparing expected tuberculosis deaths, modelled with trends in tuberculosis deaths from 2015 to 2019 in vital registration data, with observed tuberculosis deaths in 2020 and 2021 for countries with available cause-specific mortality data. FINDINGS: We estimated 9·40 million (95% uncertainty interval [UI] 8·36 to 10·5) tuberculosis incident cases and 1·35 million (1·23 to 1·52) deaths due to tuberculosis in 2021. At the global level, the all-age tuberculosis incidence rate declined by 6·26% (5·27 to 7·25) between 2015 and 2020 (the WHO End TB strategy evaluation period). 15 of 204 countries achieved a 20% decrease in all-age tuberculosis incidence between 2015 and 2020, eight of which were in western sub-Saharan Africa. When stratified by age, global tuberculosis incidence rates decreased by 16·5% (14·8 to 18·4) in children younger than 5 years, 16·2% (14·2 to 17·9) in those aged 5-14 years, 6·29% (5·05 to 7·70) in those aged 15-49 years, 5·72% (4·02 to 7·39) in those aged 50-69 years, and 8·48% (6·74 to 10·4) in those aged 70 years and older, from 2015 to 2020. Global tuberculosis deaths decreased by 11·9% (5·77 to 17·0) from 2015 to 2020. 17 countries attained a 35% reduction in deaths due to tuberculosis between 2015 and 2020, most of which were in eastern Europe (six countries) and central Europe (four countries). There was variable progress by age: a 35·3% (26·7 to 41·7) decrease in tuberculosis deaths in children younger than 5 years, a 29·5% (25·5 to 34·1) decrease in those aged 5-14 years, a 15·2% (10·0 to 20·2) decrease in those aged 15-49 years, a 7·97% (0·472 to 14·1) decrease in those aged 50-69 years, and a 3·29% (-5·56 to 9·07) decrease in those aged 70 years and older. Removing the combined effects of the three attributable risk factors would have reduced the number of all-age tuberculosis deaths from 1·39 million (1·28 to 1·54) to 1·00 million (0·703 to 1·23) in 2020, representing a 36·5% (21·5 to 54·8) reduction in tuberculosis deaths compared to those observed in 2015. 41 countries were included in our analysis of the impact of the COVID-19 pandemic on tuberculosis deaths without HIV co-infection in 2020, and 20 countries were included in the analysis for 2021. In 2020, 50 900 (95% CI 49 700 to 52 400) deaths were expected across all ages, compared to an observed 45 500 deaths, corresponding to 5340 (4070 to 6920) fewer deaths; in 2021, 39 600 (38 300 to 41 100) deaths were expected across all ages compared to an observed 39 000 deaths, corresponding to 657 (-713 to 2180) fewer deaths. INTERPRETATION: Despite accelerated progress in reducing the global burden of tuberculosis in the past decade, the world did not attain the first interim milestones of the WHO End TB Strategy in 2020. The pace of decline has been unequal with respect to age, with older adults (ie, those aged >50 years) having the slowest progress. As countries refine their national tuberculosis programmes and recalibrate for achieving the 2035 targets, they could consider learning from the strategies of countries that achieved the 2020 milestones, as well as consider targeted interventions to improve outcomes in older age groups. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024. PMID: 38518787. doi:10.1016/S1473-3099(24)00007-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。